APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Phase 2 Recruiting
152 enrolled
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Phase 2 Recruiting
164 enrolled
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2 Recruiting
30 enrolled
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Phase 2 Recruiting
36 enrolled
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
Phase 2 Recruiting
49 enrolled
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 Recruiting
39 enrolled
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
Phase 2 Recruiting
40 enrolled
APSOC
Phase 2 Recruiting
73 enrolled
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Phase 2 Recruiting
164 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2 Recruiting
25 enrolled
PEMIGIST
Phase 2 Recruiting
24 enrolled
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Phase 2 Recruiting
37 enrolled
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Phase 2 Recruiting
740 enrolled
CANTOR
Phase 2 Recruiting
120 enrolled
SAFE ESO
Phase 2 Recruiting
95 enrolled
NEOPRISM-CRC
Phase 2 Recruiting
88 enrolled
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2 Recruiting
294 enrolled
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Phase 2 Recruiting
27 enrolled
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Phase 2 Recruiting
38 enrolled
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Phase 2 Recruiting
46 enrolled
LUCENT-GC-03
Phase 2 Recruiting
73 enrolled
LUCENT-GC-02
Phase 2 Recruiting
108 enrolled
TATE-PD1
Phase 2 Recruiting
54 enrolled
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 Recruiting
110 enrolled
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Phase 2 Recruiting
216 enrolled
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Phase 2 Recruiting
24 enrolled
ABLATE
Phase 2 Recruiting
43 enrolled
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
Phase 2 Recruiting
60 enrolled
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
Phase 2 Recruiting
15 enrolled
PSI-Immune
Phase 2 Recruiting
880 enrolled
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Phase 2 Recruiting
60 enrolled
PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Phase 2 Recruiting
78 enrolled
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Phase 2 Recruiting
100 enrolled
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Phase 2 Recruiting
89 enrolled
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Phase 2 Recruiting
327 enrolled
GABRINOX2
Phase 2 Recruiting
162 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
INDIGO-FAPI
Phase 2 Recruiting
35 enrolled
AndroMETa-CRC
Phase 2 Recruiting
390 enrolled
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Phase 2 Recruiting
36 enrolled
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
Phase 2 Recruiting
30 enrolled
INS-ESCC-CT
Phase 2 Recruiting
118 enrolled
STELLAR01
Phase 2 Recruiting
98 enrolled
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
40 enrolled
SLIDE-HCC
Phase 2 Recruiting
140 enrolled
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Phase 2 Recruiting
30 enrolled
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
Phase 2 Recruiting
44 enrolled
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Phase 2 Recruiting
36 enrolled
Obeticholic Acid for Prevention in Barrett's Esophagus
Phase 2 Recruiting
30 enrolled
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Phase 2 Recruiting
95 enrolled